Addressing the Data Gaps on Child and Adolescent Tuberculosis.
tuberculosis
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
08
01
2022
revised:
11
02
2022
accepted:
17
02
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
The burden of tuberculosis (TB) among children and young adolescents (<15 years old) is estimated at 1.1 million; however, only 400,000 are treated for TB, indicating a large gap between the number who are cared for and the number estimated to have TB. Accurate data on the burden of pediatric TB is essential to guide action. Despite several improvements in estimating the burden of pediatric TB in the last decade, as well as enhanced data collection efforts, several data gaps remain, both at the global level, but also at the national level where surveillance systems and collaborative research are critical. In this article, we describe recent advances in data collection and burden estimates for TB among children and adolescents, and the remaining gaps. While data collection continues to improve, burden estimates must evolve in parallel, both in terms of their frequency and the methods used. Currently, at the global level, there is a focus on age-disaggregation of TB notifications, the collection of data on TB-HIV, multi-drug resistant (MDR)-TB and treatment outcomes, as well as estimates of the disease burden. Additional data from national surveillance systems or research projects on TB meningitis, as well as other forms of extra-pulmonary TB, would be useful. We must capitalize on the current momentum in child and adolescent TB to close the remaining data gaps for these age groups to better understand the epidemic and further reduce morbidity and mortality due to TB.
Identifiants
pubmed: 35335677
pii: pathogens11030352
doi: 10.3390/pathogens11030352
pmc: PMC8955570
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NIH HHS
ID : R03 AI164123
Pays : United States
Organisme : NIAID NIH HHS
ID : L40 AI141492
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152126
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI164123
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : FIC NIH HHS
ID : K01 TW010829
Pays : United States
Organisme : NIH HHS
ID : R01 AI152126
Pays : United States
Références
Public Health Action. 2016 Jun 21;6(2):83-96
pubmed: 27358801
Lancet Infect Dis. 2016 Oct;16(10):1193-1201
pubmed: 27342768
Clin Infect Dis. 2021 Dec 20;:
pubmed: 34929028
Lancet Child Adolesc Health. 2022 Feb;6(2):106-115
pubmed: 34800370
Lancet Respir Med. 2019 Jun;7(6):544-552
pubmed: 31078497
Lancet Glob Health. 2014 Aug;2(8):e453-9
pubmed: 25103518
Lancet. 2014 May 3;383(9928):1572-9
pubmed: 24671080
Lancet Glob Health. 2022 Mar;10(3):e337-e347
pubmed: 35180417
PLoS Med. 2018 Jul 11;15(7):e1002591
pubmed: 29995958
Lancet Infect Dis. 2017 Mar;17(3):285-295
pubmed: 27964822
Lancet Child Adolesc Health. 2020 Jan;4(1):68-79
pubmed: 31753806
Int J Epidemiol. 2021 May 17;50(2):570-577
pubmed: 33624797
ERJ Open Res. 2020 Sep 14;6(3):
pubmed: 32964003
Eur Respir J. 2018 Feb 21;51(2):
pubmed: 29467206
Lancet Infect Dis. 2018 Mar;18(3):261-284
pubmed: 29223583
Lancet Glob Health. 2021 Dec;9(12):e1679-e1687
pubmed: 34798027
Lancet Glob Health. 2017 Sep;5(9):e898-e906
pubmed: 28807188
PLoS One. 2019 Dec 30;14(12):e0227186
pubmed: 31887208
J Int AIDS Soc. 2021 Sep;24 Suppl 5:e25791
pubmed: 34546661
Lancet Glob Health. 2022 Feb;10(2):e207-e215
pubmed: 34895517
Lancet Infect Dis. 2021 Jul;21(7):984-992
pubmed: 33640076
Lancet Infect Dis. 2014 Oct;14(10):947-57
pubmed: 25108337